vs
TETRA TECHNOLOGIES INC（TTI）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
TETRA TECHNOLOGIES INC的季度营收约是再鼎医药的1.2倍（$156.3M vs $127.1M），再鼎医药同比增速更快（17.1% vs -0.6%），再鼎医药自由现金流更多（$-26.7M vs $-31.9M），过去两年再鼎医药的营收复合增速更高（20.8% vs -4.7%）
Tetra Tech是一家总部位于美国加利福尼亚州帕萨迪纳的咨询与工程服务企业，业务覆盖水资源、生态环境、基础设施、资源管理、能源及国际发展等领域，可提供专业咨询、工程设计、项目管理与施工管理等多元化服务。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
TTI vs ZLAB — 直观对比
营收规模更大
TTI
是对方的1.2倍
$127.1M
营收增速更快
ZLAB
高出17.7%
-0.6%
自由现金流更多
ZLAB
多$5.2M
$-31.9M
两年增速更快
ZLAB
近两年复合增速
-4.7%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $156.3M | $127.1M |
| 净利润 | $8.3M | — |
| 毛利率 | 24.5% | 51.0% |
| 营业利润率 | 8.2% | -54.6% |
| 净利率 | 5.3% | — |
| 营收同比 | -0.6% | 17.1% |
| 净利润同比 | 105.5% | — |
| 每股收益（稀释后） | — | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收TTIZLAB
| Q1 26 | $156.3M | — | ||
| Q4 25 | $146.7M | $127.1M | ||
| Q3 25 | $153.2M | $115.4M | ||
| Q2 25 | $173.9M | $109.1M | ||
| Q1 25 | $157.1M | $105.7M | ||
| Q4 24 | $134.5M | $108.5M | ||
| Q3 24 | $141.7M | $101.8M | ||
| Q2 24 | $171.9M | $100.1M |
净利润TTIZLAB
| Q1 26 | $8.3M | — | ||
| Q4 25 | $-16.5M | — | ||
| Q3 25 | $4.2M | $-36.0M | ||
| Q2 25 | $11.3M | $-40.7M | ||
| Q1 25 | $4.0M | $-48.4M | ||
| Q4 24 | $102.7M | — | ||
| Q3 24 | $-3.0M | $-41.7M | ||
| Q2 24 | $7.6M | $-80.3M |
毛利率TTIZLAB
| Q1 26 | 24.5% | — | ||
| Q4 25 | 19.4% | 51.0% | ||
| Q3 25 | 23.7% | 59.5% | ||
| Q2 25 | 27.7% | 60.6% | ||
| Q1 25 | 27.3% | 63.6% | ||
| Q4 24 | 23.1% | 61.5% | ||
| Q3 24 | 24.3% | 64.1% | ||
| Q2 24 | 25.2% | 64.9% |
营业利润率TTIZLAB
| Q1 26 | 8.2% | — | ||
| Q4 25 | -4.2% | -54.6% | ||
| Q3 25 | 7.3% | -42.3% | ||
| Q2 25 | 11.2% | -50.3% | ||
| Q1 25 | 3.2% | -53.3% | ||
| Q4 24 | 5.5% | -62.6% | ||
| Q3 24 | 8.4% | -66.6% | ||
| Q2 24 | 7.3% | -76.0% |
净利率TTIZLAB
| Q1 26 | 5.3% | — | ||
| Q4 25 | -11.3% | — | ||
| Q3 25 | 2.7% | -31.2% | ||
| Q2 25 | 6.5% | -37.3% | ||
| Q1 25 | 2.6% | -45.8% | ||
| Q4 24 | 76.4% | — | ||
| Q3 24 | -2.1% | -40.9% | ||
| Q2 24 | 4.4% | -80.2% |
每股收益（稀释后）TTIZLAB
| Q1 26 | — | — | ||
| Q4 25 | $-0.12 | $-0.05 | ||
| Q3 25 | $0.03 | $-0.03 | ||
| Q2 25 | $0.08 | $-0.04 | ||
| Q1 25 | $0.03 | $-0.04 | ||
| Q4 24 | $0.77 | $-0.09 | ||
| Q3 24 | $-0.02 | $-0.04 | ||
| Q2 24 | $0.06 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $35.5M | $689.6M |
| 总债务越低越好 | $5.9M | — |
| 股东权益账面价值 | $285.6M | $715.5M |
| 总资产 | $662.3M | $1.2B |
| 负债/权益比越低杠杆越低 | 0.02× | — |
8季度趋势，按日历期对齐
现金及短期投资TTIZLAB
| Q1 26 | $35.5M | — | ||
| Q4 25 | $72.6M | $689.6M | ||
| Q3 25 | $67.1M | $717.2M | ||
| Q2 25 | $68.7M | $732.2M | ||
| Q1 25 | $41.0M | $757.3M | ||
| Q4 24 | $37.0M | $779.7M | ||
| Q3 24 | $48.4M | $616.1M | ||
| Q2 24 | $37.7M | $630.0M |
总债务TTIZLAB
| Q1 26 | $5.9M | — | ||
| Q4 25 | $190.0M | — | ||
| Q3 25 | $180.9M | — | ||
| Q2 25 | $180.5M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $179.7M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $179.7M | — |
股东权益TTIZLAB
| Q1 26 | $285.6M | — | ||
| Q4 25 | $283.8M | $715.5M | ||
| Q3 25 | $296.7M | $759.9M | ||
| Q2 25 | $290.9M | $791.7M | ||
| Q1 25 | $273.0M | $810.8M | ||
| Q4 24 | $254.6M | $840.9M | ||
| Q3 24 | $156.7M | $667.7M | ||
| Q2 24 | $154.8M | $704.2M |
总资产TTIZLAB
| Q1 26 | $662.3M | — | ||
| Q4 25 | $675.8M | $1.2B | ||
| Q3 25 | $655.2M | $1.2B | ||
| Q2 25 | $645.6M | $1.2B | ||
| Q1 25 | $614.1M | $1.2B | ||
| Q4 24 | $605.2M | $1.2B | ||
| Q3 24 | $501.2M | $985.3M | ||
| Q2 24 | $605.2M | $987.4M |
负债/权益比TTIZLAB
| Q1 26 | 0.02× | — | ||
| Q4 25 | 0.67× | — | ||
| Q3 25 | 0.61× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.71× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.16× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $-31.9M | $-26.7M |
| 自由现金流率自由现金流/营收 | -20.4% | -21.0% |
| 资本支出强度资本支出/营收 | 4.5% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $1.6M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流TTIZLAB
| Q1 26 | — | — | ||
| Q4 25 | $31.7M | $-26.0M | ||
| Q3 25 | $16.4M | $-32.0M | ||
| Q2 25 | $48.3M | $-31.0M | ||
| Q1 25 | $3.9M | $-61.7M | ||
| Q4 24 | $5.6M | $-55.8M | ||
| Q3 24 | $19.9M | $-26.8M | ||
| Q2 24 | $24.8M | $-42.2M |
自由现金流TTIZLAB
| Q1 26 | $-31.9M | — | ||
| Q4 25 | $4.1M | $-26.7M | ||
| Q3 25 | $627.0K | $-35.0M | ||
| Q2 25 | $28.8M | $-33.9M | ||
| Q1 25 | $-14.0M | $-63.2M | ||
| Q4 24 | $-9.3M | $-58.4M | ||
| Q3 24 | $5.3M | $-28.2M | ||
| Q2 24 | $9.4M | $-42.9M |
自由现金流率TTIZLAB
| Q1 26 | -20.4% | — | ||
| Q4 25 | 2.8% | -21.0% | ||
| Q3 25 | 0.4% | -30.4% | ||
| Q2 25 | 16.6% | -31.1% | ||
| Q1 25 | -8.9% | -59.9% | ||
| Q4 24 | -6.9% | -53.8% | ||
| Q3 24 | 3.7% | -27.7% | ||
| Q2 24 | 5.5% | -42.9% |
资本支出强度TTIZLAB
| Q1 26 | 4.5% | — | ||
| Q4 25 | 18.8% | 0.5% | ||
| Q3 25 | 10.3% | 2.6% | ||
| Q2 25 | 11.2% | 2.6% | ||
| Q1 25 | 11.4% | 1.5% | ||
| Q4 24 | 11.1% | 2.4% | ||
| Q3 24 | 10.3% | 1.3% | ||
| Q2 24 | 9.0% | 0.7% |
现金转化率TTIZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 3.94× | — | ||
| Q2 25 | 4.28× | — | ||
| Q1 25 | 0.97× | — | ||
| Q4 24 | 0.05× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 3.25× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
TTI
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
